Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic data for the 151 patients

From: Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study

Patients 82.8% women
Age (years) 51.4 ± 13.2
Anti-CCP 80.1% positive
Rheumatoid factor 75.2% positive
Disease duration (years) 9.9 ± 7.9
Number of swollen joints 6.49 ± 5.5
Number of tender joints 5.98 ± 6.4
bDMARDs initiated in the study cohort Infliximab (n = 19), etanercept (n = 59), adalimumab (n = 8), certolizumab (n = 12), golimumab (n = 8), rituximab (n = 30), tocilizumab (n = 8), and abatacept (n = 5); 8% of the patients were biologic naive
Prednisolone treated 50.7%
Prednisolone dose 7.8 ± 4.68 mg
DAS28-CRP score 4.14 ± 1.32)
Total number of joints examined, n 5225
Joints with SH and no Doppler at baseline, n (%) 1191 (23%)
Joints with SH and Doppler at baseline, n (%) 1151 (22%)
  1. Values are shown as mean ± standard deviation unless otherwise indicated
  2. bDMARD biological disease-modifying antirheumatic drug, CCP cyclic citrullinated peptide, DAS28-CRP Disease Activity Score 28-joint count C-reactive peptide, SH synovial hypertrophy